NCT05678335

Tacrolimus for Thrombocytopenia in SS

Tacrolimus for Mild Thrombocytopenia in Sjogren's Syndrome

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.

Detailed description

This study evaluates the efficacy and safety of Tacrolimus for the treatment of thrombocytopenia in Sjogren's syndrome patients.

Conditions

• Sjogren Syndrome With Other Organ Involvement

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Oral hydroxychloroquine 200mg twice daily for 12weeks.
DRUG	Tacrolimus	Oral Tacrolimus 1-2mg twice daily for 12 weeks.

Timeline

• Start date: 2023-02-01
• Primary completion: 2023-12-01
• Completion: 2024-03-01
• First posted: 2023-01-10
• Last updated: 2023-01-10